ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Carcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Colorectal Cancer

Lung Cancer trials near Chicago, IL, USA:

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (ARC-10)

to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Phase 2

Arcus Biosciences
Arcus Biosciences

Hinsdale, Illinois, United States and 117 other locations

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Chicago, Illinois, United States and 48 other locations

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Chicago, Illinois, United States and 209 other locations

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Platinum-Based Doublet

Phase 2

Gilead Sciences
Gilead Sciences

Chicago, Illinois, United States and 52 other locations

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Chicago, Illinois, United States and 123 other locations

This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: sigvotatug vedotin
Drug: docetaxel

Phase 3

Seagen
Seagen

Niles, Illinois, United States and 140 other locations

in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...

Enrolling
Extensive Stage-small Cell Lung Cancer
Drug: Carboplatin
Drug: Ifinatamab deruxtecan

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

Chicago, Illinois, United States and 48 other locations

N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study ...

Active, not recruiting
Stage IIIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Procedure: Surgery
Radiation: Radiotherapy

Phase 2

Alliance Foundation Trials

Chicago, Illinois, United States and 8 other locations

with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Niles, Illinois, United States and 210 other locations

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Cisplatin
Drug: Alectinib

Phase 2

AstraZeneca
AstraZeneca

Chicago, Illinois, United States and 46 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems